Increased levels of serum serglycin and agrin is associated with adverse perinatal outcome in early onset preeclampsia
Yükleniyor...
Dosyalar
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Taylor & Francis Inc
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Goal: Our aim was to determine whether alterations in serum serglycin and agrin levels in early-onset preeclampsia (EOPE) are useful in predicting adverse perinatal outcomes such as fetal growth restriction (FGR), intrauterine fetal demise (IUFD), preterm delivery and/or neonatal unit admission. Materials and Methods: A prospective case-controlled study enrolled 88 pregnant patients (44 EOPE and 44 controls). Maternal serum serglycin and agrin levels were determined before the 34th gestational week by enzyme-linked immunosorbent assay. Results: Compared with controls, women with EOPE had significantly higher serglycin and agrin levels (p = .018; p = .048). Multivariable logistic regression analysis revealed serglycin was independently associated with FGR in EOPE (OR 0.866; 95% CI 0.779-0.953). Agrin was independently associated with IUFD in EOPE (OR 0.757, 95% CI 0.636-0.879). Conclusions: The current study suggests that increased maternal serum serglycin is associated with FGR, and increased maternal serum agrin is associated with IUFD in EOPE.
Açıklama
Anahtar Kelimeler
Early Onset Preeclampsia, Serglycin, Agrin, Fetal Growth Restriction, Intrauterine Fetal Demise, Adverse Perinatal, Maternal Outcomes
Kaynak
Fetal and Pediatric Pathology
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
38
Sayı
5
Künye
Gumus Guler, B., & Ozler, S. (2019). Increased levels of serum serglycin and agrin is associated with adverse perinatal outcome in early onset preeclampsia. Fetal and pediatric pathology, 38(5), 418-431.
